Withdrawal From Substance Disorder
Resources for Patients and Caregivers
Cluster Number:
Wiki Number: 57-Withdrawal from Substance Disorder
Diagnosis:
US Patients:
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms:
Progression:
Causes:
Medications:
Therapies:
Youtube Video:
Alcohol Withdrawal Syndrome and Delerium Tremens
Amazon or Library Book: Alcoholism and Addiction Recovery
Click the book to link or order from Amazon.
Support Group: samhsa.gov; 800-662-4357
(U. S. Government Helpline)
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- A Sustained H2/Fluorouracil-Releasing Suppository for High-efficacy and Low-Toxicity Hydrogenochemotherapy of Colon Cancerby Danyang Chen on January 22, 2025
To attenuate the intestinal toxicity of chemotherapeutic drugs from rectal suppositories and enhance their chemotherapeutic outcome is greatly significant, but maintains a challenge. In this work, a new strategy of local synergistic hydrogenochemotherapy is proposed to attenuate side effects and enhance therapeutic efficacy based on the anti-cancer selectivity and normal cells-protecting effect of H(2), and construct a novel anti-cancer formulation of rectal suppository (5-FU/CSN@FAG) by fatty...
- Active withdrawal of corticosteroids using tocilizumab and its association with autoantibody profiles in relapsed Takayasu arteritis: a multicentre, single-arm, prospective study (the Ab-TAK study)by Tsuyoshi Shirai on January 22, 2025
CONCLUSION: CW using TCZ was achieved in 44.4% of patients with TAK relapse and was significantly higher in E+ and S+ patients. CW can be a feasible target, and the precise selection of patients is critical.
- A pilot study of ketamine among individuals with tobacco use disorder: tolerability and initial impact on tobacco use outcomesby Janice Chuang on January 21, 2025
CONCLUSIONS: Although limited by the small sample size, this pilot study extends previous research on ketamine for substance use disorders. While ketamine was well tolerated in this sample, additional research testing different ketamine doses and administration routes is necessary to determine whether ketamine has therapeutic potential for tobacco use disorder.
- Network Pharmacology Combined With Metabolomics Reveals the Mechanism of Yangxuerongjin Pill Against Type 2 Diabetic Peripheral Neuropathy in Ratsby Ran Jin on January 21, 2025
CONCLUSION: YXRJP can effectively improve the symptoms of DPN rats and reduce nerve damage. The effects are mainly related to reducing oxidative stress injury, promoting the expression of neuroprotection-related proteins, reducing the expression of inflammation-related proteins, and affecting amino acid metabolism, lipid metabolism, and nucleotide metabolism pathways. Our findings revealed that YXRJP has a good therapeutic potential for DPN, which provides a reference for further studies on...